Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Real-World Data Support Bevacizumab-Based Quadruplet Therapy in Frontline Advanced Cervical Cancer

August 8th 2025

Alberto Farolfi, MD, PhD, shares results from a real-world study of first-line bevacizumab, pembrolizumab, and platinum chemotherapy in cervical cancer.

Final Phase 3 Data Underscore Role of Pembrolizumab/Chemoradiotherapy in High Risk, Locally Advanced Cervical Cancer

August 1st 2025

Linda Duska, MD, MPH, discusses final results of KEYNOTE A18 for pembrolizumab plus chemoradiotherapy in high risk, locally advanced cervical cancer.

Endometrial Cancer: Future Directions and Unmet Needs

July 31st 2025

Panelists discuss how emerging antibody-drug conjugates targeting B7-H4 and folate receptors are showing unprecedented 40% to 50% response rates in recurrent endometrial cancer, representing a paradigm shift from historical treatment limitations while highlighting the exciting but challenging landscape of sequencing multiple novel therapies.

Optimizing Therapy for MMR-Proficient Endometrial Cancer

July 31st 2025

Panelists discuss how the DUO trial demonstrates the benefit of durvalumab in adjuvant endometrial cancer treatment and suggests potential value of adding olaparib in specific subgroups like mismatch repair–proficient patients, though emphasizing the need for confirmatory studies before routine clinical implementation.

RUBY Trial: Real-World Safety, Efficacy Analysis, and Quality of Life Considerations in Endometrial Cancer

July 24th 2025

Panelists discuss how the RUBY trial’s real-world data confirms the efficacy of dostarlimab maintenance therapy and surprisingly shows improved quality of life outcomes with delayed time to deterioration compared to placebo, providing confidence in using immunotherapy maintenance despite potential adverse effects.

SIENDO Study: Long-Term Safety and Efficacy of Selinexor Maintenance in Endometrial Cancer

July 24th 2025

Panelists discuss how selinexor shows remarkable efficacy in patients with mismatch repair–proficient endometrial cancer, with 40-month progression-free survival compared to 5 months with standard care, while emphasizing the importance of ongoing clinical trials to validate biomarker-driven treatment decisions.

Analysis Links ctDNA Clearance to Improved Outcomes in Advanced Cervical Cancer

July 23rd 2025

Jyoti S. Mayadev, MD, discusses a ctDNA analysis from the CALLA study of chemoradiation with or without durvalumab in locally advanced cervical cancer.

Dr Markman on Future Research Directions in Gynecologic Oncology

July 21st 2025

Maurie Markman, MD, discusses future research considerations in gynecologic oncology.

Nimotuzumab Plus Chemotherapy Yields Survival Benefits in Frontline Recurrent/Persistent Cervical Cancer

July 18th 2025

Nimotuzumab plus chemotherapy was more effective than chemotherapy alone in patients with recurrent or persistent cervical cancer.

Dr Duska on PFS2 Data With Pembrolizumab and Chemoradiotherapy in Cervical Cancer

July 17th 2025

Linda R. Duska, MD, MPH, discusses PFS2 data with pembrolizumab plus chemoradiotherapy in newly diagnosed, high-risk cervical cancer.

Biomarker Testing and Treatment Selection in Advanced Endometrial Cancer

July 17th 2025

Panelists discuss how endometrial cancer treatment has been revolutionized through molecular subtyping into 4 distinct groups (POLE hypermutated, microsatellite instability-high, p53 mutated, and no specific molecular pathology), enabling personalized treatment approaches based on tumor biology rather than just staging.

Advanced Cervical Cancer: Novel Immunotherapy Combinations and Future Treatment Paradigms

July 17th 2025

Panelists discuss how the field is expanding with newer antibody-drug conjugates targeting TROP2, combination immunotherapy approaches, and the critical importance of HPV vaccination as prevention, while addressing social barriers to complex treatment regimens.

Dr Mayadev on a ctDNA Analysis of the CALLA Trial in Cervical Cancer

July 15th 2025

Jyoti Mayadev, MD, discusses the value of ctDNA as a prognostic biomarker for relapse and survival in patients with locally advanced cervical cancer.

Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer

July 11th 2025

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

ADC Treatment Strategies in Cervical Cancer: Clinical Implementation and Emerging Treatment Options

July 10th 2025

Panelists discuss how tisotumab vedotin represents a practice-changing but modest improvement in cervical cancer treatment, with only 1.5-month progression-free survival benefit and notable ocular toxicities, while emphasizing the need for better patient access to required ophthalmologic monitoring.

Advanced Cervical Cancer Treatment Landscape: Clinical Decision-Making and Biomarker Integration

July 10th 2025

Panelists discuss how cervical cancer treatment guidelines have rapidly evolved to incorporate pembrolizumab across multiple settings, from locally advanced disease with positive nodes to metastatic disease, while emphasizing the importance of comprehensive biomarker testing including PD-L1 and HER2 status for optimal treatment selection.

Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer

July 1st 2025

Bhavana Pothuri, MD, discusses remaining unmet needs for patients with recurrent/advanced endometrial cancer.

Recent Advances and Future Direction in Ovarian Cancer Treatments

July 1st 2025

Panelists discuss how the recent approval of avutometinib plus defactinib for KRAS-mutated low-grade serous ovarian cancer addresses a significant unmet need in this lethal disease, with the dual FAK/MEK inhibition approach showing impressive response rates despite requiring careful toxicity management.

The Evolving Ovarian Cancer ADC Landscape

July 1st 2025

Panelists discuss how the emerging pipeline of folate receptor-targeted antibody-drug conjugates, including rinatabart sesutecan (Rina-S) and other novel compounds, offers diverse payload options and potentially broader patient eligibility with different toxicity profiles, though sequencing strategies remain to be determined.

Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer

June 25th 2025

Selinexor improved PFS, TFST, TSST, and PFS2 in TP53 wild-type advanced/recurrent endometrial cancer.